查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1751231

静脉铁市场规模、份额、趋势分析报告：依产品、应用、地区、细分市场、预测，2025 年至 2030 年

Intravenous Iron Drugs Market Size, Share, & Trends Analysis Report By Product (Iron Dextran, Iron Sucrose, Ferric Carboxymaltose), By Application (Chronic Kidney Disease), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

静脉注射铁市场的成长与趋势：

根据Grand View Research, Inc.的最新报告，全球静脉注射铁市场规模预计到2030年将达到56.2亿美元，2025年至2030年期间的复合年增长率为9.1%。

预计预测期内，产业竞争将维持在高水准。跨国公司占据了市场的大部分收益占有率。此外，成长机会吸引了新的参与者，进一步加剧了竞争对手之间的竞争。市场分散，主要企业正在采取一系列成长策略，例如策略联盟、收购和新药上市，以抢占更大的市场份额。

感染疾病带来的沉重疾病负担，加上营养不良，是该地区儿童贫血的主要原因之一。新冠疫情也导致重症患者贫血增多，在某些情况下甚至导致缺氧，进一步增加了全球对治疗贫血的铁补充剂的需求。

贫血盛行率的上升也归因于各种妇科和胃肠道疾病，这推动了静脉注射疗法在世界各地的普及。例如，同年龄层非孕妇贫血的总体盛行率为29.6%，孕妇贫血的盛行率为36.5%。由于医疗保健预算和投资的增加，预计预测期内市场将大幅成长。

口服铁补充剂的缺点包括消化器官系统问题，例​​如胃痛、便秘、食慾不振、噁心和呕吐，因此患者更倾向于静脉注射。静脉注射铁补充剂已被证明可以改善体内铁的吸收，促进促红血球生成素刺激剂 (ESA) 的分泌，并改善贫血。其他益处包括改善心臟健康，并且适用于透析患者，尤其是正在接受血液透析机的患者。

静脉注射铁市场报告重点

  • Ferric carboxymaltose因其应用范围不断扩大、性能优越、副作用较少、成本较低，在 2024 年占据了静脉铁补充剂行业的主导地位。
  • 2024年，蔗糖铁占据了市场的大部分份额。严重过敏反应的发生率低提高了这些药物的采用率。
  • 由于患有 CKD 和 CKD 相关缺铁性贫血的患者数量不断增加，预计慢性肾臟病领域将在 2024 年占据最大份额。
  • 由于对输液药物的需求量大以及胃肠道疾病、癌症和 CKD 盛行率不断上升，北美在 2024 年占据了最大的区域份额。
  • 由于未满足的需求不断增长、医疗保健成本不断上升以及现有全球参与者在当地的存在，预计亚太地区将在估计和预测期内以最快的速度增长。

目录

第一章调查方法与范围

第二章执行摘要

3. 静脉铁市场变数、趋势与范围

  • 市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析-波特五力分析
    • PESTLE分析
    • 管道分析
    • 专利到期分析
    • 定价分析

第四章静脉注射铁市场：依产品分類的业务分析

  • 2024 年及 2030 年各产品市场占有率
  • 产品细分细分仪表板
  • 市场规模、预测与趋势分析（按产品，2018-2030 年）
  • 聚葡萄糖铁
  • 蔗糖铁
  • 羧基Carboxymaltose铁
  • 其他的

第五章静脉铁市场：应用商业分析

  • 2024 年及 2030 年各应用领域的市场占有率
  • 应用程式细分仪表板
  • 市场规模、预测与趋势分析（按应用，2018-2030 年）
  • 慢性肾臟病
  • 发炎性肠道疾病
  • 癌症
  • 其他疾病

第六章静脉铁製剂市场：按地区估计和趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 2018年至2030年市场规模及预测趋势分析
  • 北美洲
    • 2018-2030年各国情况
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争态势

  • 参与者概览
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • AbbVie Inc.
    • AMAG Pharmaceuticals（Covis Pharma）
    • Daiichi Sankyo Company, Ltd.
    • Sanofi
    • Vifor Pharma Management Ltd.（CSL）
    • PHARMACOSMOS A/S
    • Zydus Group
    • Rockwell Medical, Inc.
Product Code: GVR-4-68038-000-2

Intravenous Iron Drugs Market Growth & Trends:

The global intravenous iron drugs market size is expected to reach USD 5.62 billion by 2030, expanding at a CAGR of 9.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. Industry rivalry is expected to remain at a higher level over the forecast period. The market is dominated by global players accounting for most of the revenue share. Moreover, growing opportunities attract new players, which further augments the competitive rivalry. The market is fragmented and major players are involved in adopting extensive growth strategies such as entering strategic alliances, acquisitions, and new drug launches to capture a larger share.

The high disease burden of infectious diseases, coupled with poor nutrition, is one of the major causes of anemia among children in this region. The novel coronavirus pandemic has also increased anemia in severely affected patients, causing hypoxia in some cases. This has further increased the demand for intravenous iron drugs for the treatment of anemia across the globe.

The increase in the prevalence of anemia can also be attributed to various gynecological and gastrointestinal disorders, facilitating an increasing uptake of IV treatment globally. For instance, the overall prevalence of anemia is 29.6% in nonpregnant women and 36.5% in pregnant women of the same age group. With growing healthcare budgets and increasing investment, the market is anticipated to grow significantly during the forecast period.

Drawbacks of oral iron drugs such as digestive problems such as stomach aches, constipation, loss of appetite, nausea, and vomiting are reasons for patients to prefer intravenous drugs. The use of intravenous iron drugs has been shown to bring about increased iron adoption by the body, facilitating Erythropoiesis-stimulating Agents (ESAs) to function in an enhanced manner to improve the anemic condition. Other advantages are the preservation of heart health and the ability to be used by dialysis patients, especially those undergoing hemodialysis.

Intravenous Iron Drugs Market Report Highlights:

  • Ferric carboxymaltose dominated the intravenous iron drugs industry in 2024 due to its increasing application, superior performance coupled with fewer adverse effects, and reduced cost.
  • Iron sucrose held a significant share of the market in 2024. A low rate of severe allergic reactions has increased the adoption rate of these drugs.
  • The chronic kidney disease segment held the largest share in 2024, due to the increasing prevalence of CKD and CKD-associated iron deficiency anemia cases.
  • North America held the largest regional share in 2024 due to the high demand for intravenous drugs and the increasing prevalence of GI disorders, cancer, and CKD.
  • Asia Pacific is estimated to exhibit the fastest growth over the forecast period attributed to growing unmet patient needs, increasing healthcare expenditure, and the local presence of established global players.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Intravenous Iron Drugs Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Intravenous Iron Drugs Market: Product Business Analysis

  • 4.1. Product Market Share, 2024 & 2030
  • 4.2. Product Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. Iron Dextran
    • 4.4.1. Iron Dextran Market, 2018 - 2030 (USD Million)
  • 4.5. Iron Sucrose
    • 4.5.1. Iron Sucrose Market, 2018 - 2030 (USD Million)
  • 4.6. Ferric Carboxymaltose
    • 4.6.1. Ferric Carboxymaltose Market, 2018 - 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Intravenous Iron Drugs Market: Application Business Analysis

  • 5.1. Application Market Share, 2024 & 2030
  • 5.2. Application Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Chronic Kidney Disease
    • 5.4.1. Chronic Kidney Diseases Market, 2018 - 2030 (USD Million)
  • 5.5. Inflammatory Bowel Disease
    • 5.5.1. Inflammatory Bowel Disease Market, 2018 - 2030 (USD Million)
  • 5.6. Cancer
    • 5.6.1. Cancer Market, 2018 - 2030 (USD Million)
  • 5.7. Other Diseases
    • 5.7.1. Other Diseases Market, 2018 - 2030 (USD Million)

Chapter 6. Intravenous Iron Drugs Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030
  • 6.4. North America
    • 6.4.1. North America Intravenous Iron Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. UK Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Japan Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. China Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Intravenous Iron Drugs Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. AbbVie Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. AMAG Pharmaceuticals (Covis Pharma)
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Daiichi Sankyo Company, Ltd.
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Sanofi
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Vifor Pharma Management Ltd. (CSL)
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. PHARMACOSMOS A/S
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Zydus Group
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Rockwell Medical, Inc.
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global intravenous iron drugs market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 5 Global intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 6 North America intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 8 North America intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 9 U.S. intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 10 U.S. intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 11 Canada intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 12 Canada intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 13 Mexico intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 14 Mexico intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 15 Europe intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
  • Table 16 Europe intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 17 Europe intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 18 UK intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 19 UK intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 20 Germany intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 21 Germany intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 22 France intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 23 France intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 24 Italy intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 25 Italy intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 26 Spain intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 27 Spain intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 28 Norway intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 29 Norway intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 30 Denmark intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 31 Denmark intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 32 Sweden intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 33 Sweden intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 37 Japan intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 38 Japan intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 39 China intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 40 China intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 41 India intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 42 India intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 43 Australia intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 44 Australia intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 45 South Korea intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 46 South Korea intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 47 Thailand intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 48 Thailand intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 49 Latin America intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
  • Table 50 Latin America intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 51 Latin America intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 52 Brazil intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 53 Brazil intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 54 Argentina intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 55 Argentina intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 59 South Africa intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 60 South Africa intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 63 UAE intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 64 UAE intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 65 Kuwait intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 66 Kuwait intravenous iron drugs market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Intravenous iron drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Intravenous iron drugs market dynamics
  • Fig. 12 Intravenous iron drugs market: Porter's five forces analysis
  • Fig. 13 Intravenous iron drugs market: PESTLE analysis
  • Fig. 14 Product market, 2018 - 2030 (USD Million)
  • Fig. 15 Iron Dextran market, 2018 - 2030 (USD Million)
  • Fig. 16 Iron Sucrose market, 2018 - 2030 (USD Million)
  • Fig. 17 Ferric Carboxymaltose market, 2018 - 2030 (USD Million)
  • Fig. 18 Others market, 2018 - 2030 (USD Million)
  • Fig. 19 Application market, 2018 - 2030 (USD Million)
  • Fig. 20 Chronic kidney disease market, 2018 - 2030 (USD Million)
  • Fig. 21 Inflammatory bowel disease market, 2018 - 2030 (USD Million)
  • Fig. 22 Cancer market, 2018 - 2030 (USD Million)
  • Fig. 23 Other Diseases market, 2018 - 2030 (USD Million)
  • Fig. 24 Intravenous iron drugs market revenue, by region
  • Fig. 25 Regional marketplace: Key takeaways
  • Fig. 26 North America intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. country dynamics
  • Fig. 28 U.S. intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 29 Canada country dynamics
  • Fig. 30 Canada intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 31 Mexico country dynamics
  • Fig. 32 Mexico intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 33 Europe intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 34 UK country dynamics
  • Fig. 35 UK intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 36 Germany country dynamics
  • Fig. 37 Germany intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 38 France country dynamics
  • Fig. 39 France intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 40 Italy country dynamics
  • Fig. 41 Italy intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 42 Spain country dynamics
  • Fig. 43 Spain intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 44 Norway country dynamics
  • Fig. 45 Norway intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 46 Sweden country dynamics
  • Fig. 47 Sweden intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 48 Denmark country dynamics
  • Fig. 49 Denmark intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 50 Asia Pacific intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 51 Japan country dynamics
  • Fig. 52 Japan intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 53 China country dynamics
  • Fig. 54 China intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 55 India country dynamics
  • Fig. 56 India intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 57 Australia country dynamics
  • Fig. 58 Australia intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 59 South Korea country dynamics
  • Fig. 60 South Korea intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 61 Thailand country dynamics
  • Fig. 62 Thailand intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 63 Latin America intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 64 Brazil country dynamics
  • Fig. 65 Brazil intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 66 Argentina country dynamics
  • Fig. 67 Argentina intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 68 MEA intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 69 South Africa country dynamics
  • Fig. 70 South Africa intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 71 Saudi Arabia country dynamics
  • Fig. 72 Saudi Arabia intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 73 UAE country dynamics
  • Fig. 74 UAE intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 75 Kuwait country dynamics
  • Fig. 76 Kuwait intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 77 Company categorization
  • Fig. 78 Company market position analysis
  • Fig. 79 Strategic framework